Cordis’ planned acquisition of MedAlliance has been completed less than a year after it was first announced.
Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.
More from Minute Insights
• By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
• By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
• By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
• By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.